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Vitamin B2 (VB2, as an important nutrient) is eﬀectively incorporated into novel water-soluble cationic b-
cyclodextrin (b-CD) polymers in order to improve its physiochemical properties. The properties of
encapsulated VB2 are characterized by FT-IR,
1H NMR and 13C NMR for interaction between host and
guest; DSC for thermogram properties; DLS for size and size distribution; zeta potential for surface
charges and host–guest interaction types and water solubility study. The proposed novel water-soluble
cationic poly(b-CD-co-guanidine) (CAbCDP) is synthesized by b-CD and guanidine (GN) as a building
block and epichlorohydrin (EP) as a crosslinker through a one-step polymerization procedure at varying
molar ratios of GN related to EP and b-CD. These prepared polymers are characterized by FT-IR, 1H
NMR, 13C NMR, TGA, DTG, DSC, DDSC and Kjeldahl methods. In addition, the solubility of the CAbCDP in
water media, in order to recognize the eﬀect of entered GN in the solubility behaviour of CAbCDP, is
determined. The in vitro release behavior of VB2 from CAbCDPs is investigated in various simulated
physiological media, and exhibited initial burst and then slow VB2 release. It is found that the cationic
b-CD polymers with high GN content exhibit slower vitamin release compared to the others.Introduction
VB2 (Fig. 1), also known as 7,8-dimethyl-10-(10-D-ribityl)isoal-
loxazine or riboavin, is one of the B complex family members,
and is an essential vitamin for normal human health.1 It is ex-
pected that homeostatic changes of VB2 induce negative health
outcomes, such as damaging changes in the nervous system,
anemia, cataracts and growth retardation.2 This vitamin has
a key role in the oxidation–reduction of carbohydrates, lipids,
amino acid metabolism and certain vitamins (vitamin B6 and
folate). It is the precursor of avin adenine dinucleotide (FAD)
and avin mononucleotide (FMN), important coenzymes that
are essential for cellular metabolism, proliferation, growth and
survival.3 The other roles of this vitamin are anti-oxidant,4–6 anti-
inammatory properties7 and immune normal performance
role8,9 that have stated in more recent studies. It seems that VB2
has a protective role in the important tissues of the human body
from ischemia resulting of oxidative injury10 and a role in both
leukaemia and prostate cancer cells by diminish survival sig-
nalling. A numerous circumstances such as diabetes mellitus,
chronic alcoholism,11,12 Inammatory Bowel Disease (IBD),13,14r University of Kerman, Kerman, 76169,
r University of Kerman, Kerman, 76169,
ent of Nutrition, Kerman University of
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hemistry 2016inborn errors metabolism of this vitamin like BVVL (infantile
Brown–Vialetto–Van Laere) and Fazio Londe syndromes15–18 are
examples in which deciency or suboptimal levels of this
vitamin occurs. Optimizing body homeostasis of VB2 is eﬀective
in management of disease such as in BVVL patients,15–18 as well
as in B2-responsive multiple acyl-CoA dehydrogenase deciency
patients.19,20 Humans and other mammals cannot synthesize
the VB2 endogenously, so they should receive this vitamin
exogenously from food source typically.21 Chemically, the VB2
compound is slightly water soluble and a highly sensitive to the
light.22,23 Biological and pharmacological activity of VB2 can be
reduced owing to its photo degradation and poor water solu-
bility.24–27 The development of foods fortied with VB2 is a suit-
able strategy to protect people at risk of the VB2 deciency, to
prevent and treat some diﬀerent disorders,28,29 but, application
of this method is not easy due to the yellowish colour of this
vitamin and its capacity to produce photosensitized reactions.30Fig. 1 Chemical structure of VB2.
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RSC Advances PaperThere have been performed various methods to improve pho-
tostability and solubility of VB2.
Nowadays, encapsulation technology is growing to protect
the enclosed substances from the surrounding environment, to
increase their eﬃciency and to achieve their controlled
release.31,32 Numerous encapsulating compounds such as poly-
mers, vesicles, micelles and hydrogels have been proposed in
themost studies recently.31–33 Among them, b-CDs are one of the
most interested compound in this regard.33,34
The b-CD is the macrocyclic oligosaccharide that is
composed of D-glucose units join to each other by a-1,4-gluco-
sidic linkages. The shape of b-CD molecule is similar to trun-
cated cone with a hydrophobic interior cavity, including the
glycosidic oxygens and methine protons, and the hydrophilic
exterior surface, formed by secondary and primary hydroxyls on
the large and small rims. Owing to its unique cavity, b-CD can
easily form stable host–guest inclusion complexes with certain
molecules in which they t into this cavity with high selectivity.
The main driving forces behind these complexes formation are
hydrophobic and van der Waals interactions. Therefore, due to
the polarity diﬀerence between the internal and external
surfaces, bioactivity and physicochemical properties (stability,
solubility, odor, etc.) of the encapsulated guest can be notice-
ably improved. For the capabilities to form inclusion
complexes, low price, readily available and the presence of
various reactive groups on the backbone chain, b-CDs are widely
used as food additives in the food industry, for stabilization of
avors and elimination of undesired tastes.35 In addition, b-CDs
have frequently been applied in pharmacy, separation
processes, analytical sciences and catalysis, as well as in the
textile, cosmetic and packaging industry.36–40 The application of
b-CD in food industry is limited by its rather low aqueous
solubility. To overcome these limitations, numerous chemical
modication have been developed on b-CD molecule.
There have been numerous studies on the preparation of
water-soluble derivatives of b-CD molecules, which two special
categories of these derivatives are charged b-CDs and b-CD
polymers. In order to combine both the favorable properties of
charged b-CDs and b-CD polymers, a series of ionic b-CD poly-
mers were prepared using various polyfunctional crosslinking
agents.41–49 Depending on the type of crosslinking agent is used
during its polymerization some properties of b-CD, such as its
stability to heat and pH, shear forces and its solubility could be
modied. Among all the proposed crosslinkers, EP has been the
most extensively utilized bifunctional crosslinking agent in the
production of neutralized b-CD polymer due to its facile
synthesis, high sorption properties and particular selectivity.
On the other hand, existence of ionic crosslinkers in b-CD
polymers structure have been shown increased loading ability
toward diﬀerent guest due to the cooperative action between the
b-CD cavities and the surrounding ionic groups.50,51 For this
purpose, a series of cationic and anionic b-CD polymers were
prepared by using various polyfunctional crosslinking agents.
The mainly cationic b-CD polymers were synthesized by cross-
linking b-CD with EP in the presence of choline chloride.52,53
These cationic b-CD polymers have been applied in gene
delivery,54–57 in drug delivery systems as hydrogels and33268 | RSC Adv., 2016, 6, 33267–33278nanoparticles58,59 and as drug carriers52 or more particular in
glucose-sensitive multilayer lms.60,61 On the other hand,
anionic polymers were prepared from crosslinking reaction
between citric acid and b-CD.36,62 These polymers promoted
complexion capacities toward the numerous drugs63 when they
were immobilized onto biomaterial devices, for example
vascular prostheses,64,65 porous hydroxyapatite bone substi-
tutes,66 periodontal membranes67 and visceral meshes.68–70
In the last decades, diﬀerent research groups decided to
encapsulation of VB2 with CDs. In this regards, inclusion
complexes between b-CD,71–75 a-CD72 and some of its derivatives
such as 2-hydroxypropyl-b-CD (HP-b-CD)76 with VB2 have been
reported. These researches have demonstrated that VB2 can
form stable inclusion complexes (molar ratio 1 : 1) with b-CD.
Enter partial hydrophobic of VB2 into the macrocyclic cavity
causes enhancement of aqueous solubility of the encapsulated
vitamin. But, the presence of ribityl substituent in VB2 prevents
the deep penetration of this compound into b-CD cavity.
Based on the mentioned above, owing to the signicance of
cationic polymers and limitation of loading VB2 by a- and b-
CDs, we synthesised a novel water-soluble cationic b-CD poly-
mers, as a drug delivery carrier, by insertion of GN in structure
of NEbCDP. The cationic polymer structure was characterized
and their water solubility was measured. Then the VB2 (as the
model vitamin) was loaded in cationic polymers and some
properties of the obtained complexes were analyzed. In the
last step, vitamin-release behavior was also systematically
evaluated.Experimental section
Materials
b-CD was purchased from SDFCL, Mumbai. Epichlorohydrin,
vitamin B2, bromocresol green, methyl-red and membrane
dialysis tube (benzoylated, molecular weight cut-oﬀ of 2000 Da)
were purchased from Sigma-Aldrich Company. Guanidine
hydrochloride, boric acid, potassium sulfate (K2SO4), copper(II)
sulfate (Cu2SO4), sulfuric acid, hydrochloric acid (HCl), acetone
and ethanol were purchased from Merck Company. Sodium
hydroxide (NaOH) was purchased fromMojallali Company, Iran
and neutral bCD polymer (NEbCDP) was synthesized as previ-
ously described.77 Deionized (DI) water has been used in all
experiment processes.Synthesis and characterization of polymers
Synthesis of CAbCDPs. The mixture of b-CD and GN solution
in the molar ratio of 1 : 5, 1 : 10 and 1 : 15 were prepared as
follows: initially, b-CD solution was prepared by dissolving 5 g
of b-CD in 8 mL of NaOH solution (33% w/w) and then stirred
mechanically at an ambient temperature for an overnight.
Then, calculated GN powder was added to the b-CD solution.
The 3.5 mL of EP was rapidly added to the mixture. The
temperature was monitored during polymerization and kept at
30 C for 3 h and 50 min. This reaction was stopped by acetone
addition. Then acetone was removed and the aqueous solution
neutralized by addition of HCl 6 N. This solution kept at 50 CThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advancesovernight. The prepared CAbCDP solution was precipitated
using ethanol and the obtained solid washed with ethanol and
acetone for several times. The CAbCDP resultant was placed in
the air at overnight and then dried in oven at 70 C.
Determination of GN content on CAbCDP. The nitrogen
content of CAbCDPs was determined by Kjeldahl method. About
0.5 g of CAbCDPs was rst digested (digital digestion unit,
PECO) by sulfuric acid in the presence of Cu2SO4 and K2SO4.
Aer digestion, ammonia was distilled (distillation unit, PDU-
500, PECO) into boric acid solution (4% w/w) and titrated
with 0.2 N HCl using bromocresol green/methyl-red as a pH
indicator.78 The nitrogen content was calculated by the
following formula:
N% ¼ ðT  BÞ  C  14
w
 100
T: the HCl solution volume (mL) used in CAbCDP titration; B:
the HCl solution volume (mL) used in NEbCDP titration; C: the
standard HCl solution concentration (mol L1); w: the testing
sample weight (mg).
The GN content in CAbCDPs structure (Table 1) has been
calculated as follows:
GN% ¼ N%
14
 59:07
FT-IR spectrum analysis. The Fourier-transform infrared
(FT-IR) (Bruker Tensor 27) spectra were measured at an ambient
temperature in the range of 4000–400 cm1 using the potassium
bromide pellet technique.
NMR spectroscopy. Nuclear magnetic resonance (NMR)
spectra were conducted using a Varian Unity 400 spectrometer
operated at 400 MHz for proton nuclear (1H NMR) and at 100
MHz for carbon nuclear (13C NMR). Deuterated DMSO was used
as a solvent, without an internal standard.
Thermal analysis. Diﬀerential scanning calorimetry (DSC),
thermogravimetric measurements (TGA) and their derivatives
were acquired on a Netzsch (STA 409 PG, Germany) instrument.
About 15mg of samples heated from 50 C to 500 C at a heating
rate of 10 C min1 under nitrogen atmosphere (ow rate of 50
mL min1).
Aqueous solubilities of b-CD polymers. Excess amounts of
polymer samples were added to 2 mL of water, to ensure it is
saturated. The solution was mechanically shaken for 4 h and
then incubated overnight at ambient temperature. The solution
was then ltered through a sintered glass funnel (Pyrex®). The
ltrated polymers were dried in an oven for suﬃcient period
until a constant weight being reached. The solubility wasTable 1 The GN content and the yield of CAbCDPs prepared by
diﬀerent molar ratios of GN
NEbCDP CAbCDP-5 CAbCDP-10 CAbCDP-15
b-CD : EP : GN 1 : 15 : 0 1 : 15 : 5 1 : 15 : 10 1 : 15 : 15
Yield (%) 68 71 74 82
GN contents (%) 0 6.9  1.6 14  1.8 30.3  2.3
This journal is © The Royal Society of Chemistry 2016estimated from the diﬀerence between the initial amount and
the residual amount of polymers.
Preparation and characterization of CAbCDP/VB2 complexes
Preparation of CAbCDP/VB2 complexes. The CAbCDPs/VB2
complexes were prepared by using a co-precipitation method. A
300 mg of CAbCDP was dissolved in 50 mL of water, then, 6 mg
of VB2 dissolved in 50mL water was slowly added to the solution
with continuous agitation. The nal solution was maintained
for 48 h at ambient temperature until evaporation all of the
solvent. The precipitate was washed with ethanol to clear VB2
that absorbed on the surface of b-CD polymer and then it dried
in a vacuum oven at 40 C for 4 h until the weight kept constant.
These processes are performed in darkness in order to protect
VB2 from photodegradation.
Solid-state characterization. Solid-state characterization of
CAbCDPs/VB2 were performed using FT-IR,
1H NMR, 13C NMR
and DSC analyses, by the same methods which have been
described in the characterization of polymer section.
Aqueous solubilities of complexes. The solubility of
CAbCDP/VB2 complexes in water were conducted following the
conditions described previously.
Dynamic light scattering (DLS) and zeta potential. The
particle size and zeta potential of the resulting complexes were
obtained using the Zetasizer Nano Series (ZEN 3600, Malvern
Instruments Ltd., UK). These studies were directed on aqueous
solutions of samples at a constant temperature (25  0.1 C).
Zeta average size and zeta potential were calculated from the
auto-correlated function using the DTS Soware (version 5.02)
from Malvern Instruments.
In vitro release studies
In order to carry out the in vitro release study, buﬀer solutions of
pH 1.2, 7.4 and 10, were prepared. The VB2 incorporated
carriers (30 mg) were poured in 3 mL of aqueous buﬀered
solution. The mixture was conducted into a membrane dialysis
bag and then the bag was closed and transferred into a ask
containing 30 mL of buﬀer solutions of desired pH at the
physiological temperature (37 C). The release media was stir-
red gently at a constant speed of 50 rpm and a sample solution
(3 mL) was withdrawn at regular selected intervals and replaced
with equal volumes of the fresh buﬀer. The amount of released
vitamin was determined by measuring the absorbance of these
solutions spectrophotometrically at 368, 360, and 361 nm for
pH 1.2, 7.4 and 10, respectively. The amount of vitamin released
was computed by comparison of the solution absorbance with
the standard curve prepared for the pure vitamin in the
appropriate concentration in the region under the same
conditions. Since the VB2 solution is sensitive to visible light,
the release experiments were performed using glassware with
completely blackened surfaces so that the exposure of vitamin
solutions to the visible light was minimized. The cumulative
release rate of VB2 (%) was calculated as follows:
Cumulative release rateð%Þ ¼ Mt
M0
 100RSC Adv., 2016, 6, 33267–33278 | 33269
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the amount of VB2 initially loaded onto the carriers.Results and discussion
Synthesis and characterization of b-CD polymers
The preparation of water-soluble CAbCDP was designed as
a successive one step process and the reaction mechanism is
illustrated in Scheme 1. These cationic polymers were obtained
using the polymerization of b-CD and GN with EP in an alkaline
medium, which molar ratio of EP/b-CD ¼ 15 and ratio of GN/b-
CD were chosen as 5, 10 and 15. At rst, the b-CD was stirred
with an excess amount of NaOH solution in order to form
alcoholate sites. Then, GN was added to the obtained suspen-
sion. Aer addition of EP in this suspension, hydroxyl groups of
b-CD or amino groups of GN react with one reactive group of the
bifunctional agent and produce b-CD/epoxide or GN/epoxide
compounds. The obtained side chain can further react in
diﬀerent ways: (1) the epoxide ring of b-CD/epoxide can react
with another hydroxyl group of a second b-CD that resulting in
a glyceryl bridge connecting two b-CD cavities (2) the epoxide
ring of GN/epoxide can react with another amino group of
a second GN molecules and connected two GN compounds (3)
the epoxide ring of GN/epoxide can react with another hydroxylScheme 1 Schematic illustration of preparation of cationic b-CD polym
Table 2 FT-IR spectra peaks position for NEbCDP, CAbCDP-5, 10 and 1
Peaks (cm1) NEbCDP CAbCDP-5
3357 O–H stretch O–H and N–H stretch
2925–2855 CH2 stretch (asym and sym) CH2 stretch (asym and
1674 C–C stretch C–C stretch
1660 — N–H bend
1157–1030 C–O stretch C–O stretch
33270 | RSC Adv., 2016, 6, 33267–33278group of a second b-CD molecules and b-CD/epoxide can react
with another amino group of a second GNmolecules to produce
b-CD and GN in same compounds. In the last case, the modied
and unmodied b-CD and GN molecules were crosslinked into
polymer using remained EP. So, GN was graed onto the b-CD
polymer to achieve cationic b-CD polymer. The general trend
was that the amount of GN xed to the CAbCDPs increased with
increase of the initially added the GN.
FT-IR analysis. The FT-IR spectra peak position for NEbCDP
and CAbCDP-5, 10 and 15 are shown in Table 2. All of them are
chiey characterized with dominant O–H stretching vibration
(3500–3300 cm1), C–H stretching vibration (2925–2855 cm1)
and C–O stretching vibration (1157–1030 cm1), because both
b-CD and glycerol units are formed by functional units possess
a number of hydroxyl groups. On the other hand, there are four
characteristic peaks for GN compounds as follows:79 nNH at
about 3300 cm1, nC]N at 1689–1650 cm
1, dNH at about 1640
cm1 and nC–N at about 1300 cm
1. The FT-IR spectra of
CAbCDPs have characteristic groups of b-CD monomers and
cationic GN groups. In the CAbCDPs a new vibration peak at
1660 cm1 is indicative of imine group at GN, which conrmed
insertion of GN into polymers due to reaction between GN and
EP. These results establish the produce of cationic b-CD poly-
mer by graed GN onto b-CD polymers as a bridging.er through crosslinking of b-CD and GN with EP.
5
CAbCDP-10 CAbCDP-15
O–H and N–H stretch O–H and N–H stretch
sym) CH2 stretch (asym and sym) CH2 stretch (asym and sym)
C–C stretch C–C stretch
N–H bend N–H bend
C–O stretch C–O stretch
This journal is © The Royal Society of Chemistry 2016
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13C NMR analysis. The chemical structures of the CAbCDPs
were conrmed by 13C NMR spectroscopy. The 13C NMR spectra
of b-CD derivatives show an asymmetric cavity as indicated by
the signal separation of the carbon atoms characteristic. The
13C NMR spectra of NEbCDP, CAbCDP-5, 10 and 15 were ob-
tained and the results are shown in Fig. 2. In the NEbCDP, the
separated peaks at 55–81 ppm are characteristic of the signal for
C-2, C-3, C-4, C-5 and C-6 of b-CD cavities, and also carbons of
the glyceryl bridge that connecting two b-CD cavities. The peak
near 101.7 ppm is related to the C-1 which is connected to the
b-CD vertical glycosidic linkage. These results are in a good
agreement with the synthetic composition of b-CD and EP, and
the previously reported NMR results for this b-CD polymer.77 In
the spectra of CAbCDPs there are the similar separation signals
in comparison to NEbCDP, except, the distinct signals at 158.5Fig. 2 13C NMR spectra of NEbCDP, CAbCDP-5, 10 and 15 in DMSO-
d6.
This journal is © The Royal Society of Chemistry 2016ppm in CAbCDPs are assigned to the carbons of GN groups and
the signals at 44.6 ppm related to C–N are assigned to the
linkage between GN and EP. These results demonstrated that
cationic b-CD polymers containing GN groups have been
successfully prepared.
1H NMR analysis. 1H NMR spectra were also used to char-
acterize the structure of cationic b-CD polymer. The 1H NMR
spectrum of NEbCDP (Fig. 3) shows the peaks around 5.7 ppm
assigned to the O–H proton in C-2 and 3 (OH-2 and 3), peak at
4.8 ppm assigned to the C-1 proton (H-1) and peak at 4.5 ppm is
related to the proton of O–H in C-6 (OH-6) of the glucose unit
and the broadened peaks between 3 and 4 ppm correspondingFig. 3 1H NMR spectra of NEbCDP, CAbCDP-5, 10 and 15 in DMSO-d6.
RSC Adv., 2016, 6, 33267–33278 | 33271
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(H-2–6) and protons of glyceryl bridge. In the CAbCDPs, addi-
tion to the above-mentioned peaks, the weak, broadening and
even level to the base line peaks in the range of 7.1–8.5 ppm are
appeared which assigned to the N–H protons of GN. These
results are indicative that insertion of GN group in polymer has
been succeeded. The broadening and splitting peaks are
resulted from the relaxation of N14 and the slow exchange rate
of the proton on C]NH2
+.79 However, the intensity of these
peaks in CAbCDPs increases along with increasing of GN
content which this outcome is consistent with Kjeldahl data
(Table 1). These results were conrmed the reaction of b-CD and
GN with EP to produce CAbCDPs.
TGA and DTG analyses. The TGA and DTG analyses of
NEbCDP, CAbCDP-5 and CAbCDP-15 were performed and
results have been shown in Fig. 4A and B. It can be seen from
Fig. 4A, the NEbCDP illustrated two main steps of weight loss in
TGA curve. The weight loss of NEbCDP before 240 C during the
rst step was mainly due to water evaporation which may be
formed the free water of NEbCDP, and the second mass loss of
about 55.1% above 240 C was ascribed to the thermal decom-
position of NEbCDP. Aer gra of GN onto b-CD polymer, the
achieved CAbCDP-5 and 15 also show two main stages of mass
losses. The rst mass loss was found from 50 to 230 C which is
due to the water dehydration of such hydrophilic polymers. The
second mass loss was observed at temperature 230–500 C,Fig. 4 TGA (A), DTG (B), DSC (C) and DDSC (D) curves of NEbCDP, CAb
33272 | RSC Adv., 2016, 6, 33267–33278predominantly attributed to the decomposition of CAbCDP.
Moreover, the DTG curve of NEbCDP exhibits two notable peaks
centered at 271 and 342 C. These two thermal events were
related to weight losses from the polymer decomposition were
as follows; (i) decomposition of EP polymer unit at 271 C, and
(ii) mass losses due to b-CD decomposition at 342 C. Aer
insertion of GN into b-CD polymer, one main steps of weight
loss was observed in DTG curves of CAbCDPs. It was found that
all the CAbCDPs have lower peak degradation temperature in
compare with the NEbCDP. The degradation temperature of
CAbCDP decreases along with increase of GN content in the
polymer. The DTG curve of CAbCDP-15 shows the narrower
peak area in comparison with the CAbCDP-5. On the other
hand, it is notable that the CAbCDPs have high thermal stability
when temperature is above 310 C, where the CAbCDP-5 and 15
retain almost 58.1% and 63.3% of their initial masses until 500
C, while pure NEbCDP retains 55.1% of its initial mass at the
same temperatures stated above. These results conrm the
preparation of CAbCDP from reaction between b-CD, GN and
EP.
DSC and DDSC analyses. DSC and DDSC curves of pure
NEbCDP, CAbCDP-5 and 15 are presented in the Fig. 4C and D.
These compounds show an endothermic event occurring at
about 90 C due to the vaporization of the residual water.80 DSC
thermogram of NEbCDP (Fig. 4C) revealed an endothermic peak
at about 298 C that conrmed the results of TGA. In the DSCCDP-5 and 15.
This journal is © The Royal Society of Chemistry 2016
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decomposition emerged in lower temperature in comparison
with NEbCDP. As shown in DDSC curve of CAbCDP-15 (Fig. 4D),
the peak area of the decomposition polymer exhibited narrower
peak area than the CAbCDP-5. This phenomenon should be due
to the preparation of CAbCDP from reaction between the GN
and EP.
Water solubility studies. The solubility data of b-CD,
NEbCDP, CAbCDP-5, 10, 15 are summarized in Table 4. The
b-CD solubility was signicantly increased from 17.7 mg
mL1 to 875 mg mL1 by polymerization of b-CD in the
presence of EP. On the other hand, the solubility of b-CD
polymer was increased with insertion of GN in structure of
polymers. It was noted that the CAbCDPs solubility were
higher than NEbCDP. In addition, it is clearly seen that
CAbCDP water solubilities are increased along with
increasing of GN content (Table 4).Fig. 5 FT-IR spectra of CAbCDP-15 (for better comparison), VB2,
CAbCDP-5/VB2, CAbCDP-10/VB2 and CAbCDP-15/VB2.
This journal is © The Royal Society of Chemistry 2016Preparation and characterization of complexes
We have prepared inclusion complexes between VB2 and
CAbCDPs using a co-precipitation method, and then some
properties of these complexes were investigated.
FT-IR analysis. FT-IR spectra were achieved to characterize
interactions between VB2 and polymers in the solid state. Fig. 5
depicts FT-IR spectra of VB2, CAbCDP-5, 10 and 15/VB2 and also
CAbCDP-15 (for better comparison). As well known, it is not
possible to conrm the presence of an inclusion compound in
b-CD and b-CD derivatives by FT-IR,33 but clear diﬀerences
between the spectra for CAbCDPs/VB2 and the free VB2 were
observed. In the CAbCDPs/VB2 spectra absorption peaks of VB2
were disappeared, which may be due to the vitamin was
captured and distributed in the networks and cavities of the
b-CD polymers.
NMR spectroscopy. To conrm the presence of vitamin
complex, the 1H NMR and 13C NMR spectra of VB2 and its
complexes are shown in Fig. 6 and 7. As it can be seen from
Fig. 6 and 7, the assignments of 1H and 13C-chemical shi of
VB2 agree with previous reports in the literature.74,81 The
1H
NMR spectrum of VB2 in deuterated DMSO consists of the
protons H-6 and H-9 of benzene ring can be readily assigned to
peaks at 7.85 and 7.89 ppm, the aliphatic protons on carbons 1Fig. 6 1H NMR spectra of VB2, CAbCDP-5/VB2 and CAbCDP-15/VB2.
RSC Adv., 2016, 6, 33267–33278 | 33273
Fig. 7 13C NMR spectra of VB2, CAbCDP-5/VB2 and CAbCDP-15/VB2.
Fig. 8 The DSC curves of CAbCDP-15 (for better comparison) and
CAbCDP-15/VB2.
RSC Advances Paperto 5 were appeared at 4.91–4.22 ppm and also methyl group
protons (H-13 and H-12) were revealed at 2.46 and 2.38 ppm.
As shown in Fig. 6, the 1H NMR spectra of VB2 in the presence
of CAbCDP-5 and 15 were examined in order to propose the
structure of the complexes. 1H NMR spectra of the complexes
showed the proton peaks both of the CAbCDPs and VB2, which
several 1H chemical shis of VB2 have been changed. It
conrmed that the complexes were formed. Moreover, in the
presence of CAbCDPs the proton peaks of H-1–5 were overlapped
with the proton peaks of CAbCDPs, but the proton peaks of H-6,
H-9, H-12 and H-13 were clearly visible in the spectra. Therefore,
only these protons were examined upon addition of polymers
and the results have been shown in Table 3. As it follows from
Table 3, the chemical shi changes of H-6 and H-9 on VB2 have
been found 0.08 ppm and 0.02 ppm in the presence of CAbCDP-5
and also 0.1 ppm and 0.04 ppm in the presence of CAbCDP-15,
respectively. The downeld chemical shis of these protons
aer complexation of VB2 represent the environment around
these protons which are changed by the guest molecules
included. These results indicate that the benzene ring of VB2
molecule is located inside the macrocyclic cavity through inclu-
sion complex formation. However, previous researches have
shown that the benzene ring of VB2 inserted into the cavity of b-
CD, whereas its bulky ribityl side chain and the remaining two
aromatic rings are placed outside the cavity.74,81,82Table 3 1H NMR and 13C NMR chemical shift (ppm) of VB2, CAbCDP-5/
H-9 H-6 C-16
VB2 7.89 ppm 7.85 ppm 159.96 ppm
CAbCDP-5/VB2 7.97 ppm 7.87 ppm 160.33 ppm
CAbCDP-15/VB2 7.99 ppm 7.89 ppm 160.25 ppm
33274 | RSC Adv., 2016, 6, 33267–33278The 13C NMR spectrum of VB2 in deuterated DMSO have
been shown the signals of carbons 1–16 (Fig. 7). So, Fig. 7
depicts 13C NMR spectra of CAbCDPs/VB2 complexes, wherein
both CAbCDPs peaks and VB2 peaks were observed which
reveals a possible displacement of VB2 carbons resulting from
vitamin inclusion and interaction.
As can be seen in Table 3, the chemical shi of VB2 carbons
have changes in the presence of CAbCDPs compared to the free
vitamin. In the presence of CAbCDPs the downeld shis of VB2
carbons (C-6, C-9, C-12, C-15 and C-16) were due to interactions
between the species through changes in the electronic density
of VB2 upon complexation. Finally, it can be deduced from the
1H NMR spectra and previous studies that the benzene ring
entered into the inner cavity of b-CD. On the other hands, the
shielding of carbons were attributed to the inclusion and non-
inclusion complexation. Thus, whole of VB2 was included
within the b-CD cavity and polymer networks.
DSC analysis. DSC analysis is used to conrm the host–guest
interaction and thermal stability as well as to check the crys-
tallinity of VB2 in the polymer matrix. The DSC thermograms for
CAbCDP-15 and CAbCDP-15/VB2 are illustrated in Fig. 8. It is
well documented that the DSC curve of VB2 shows two transi-
tions,74 the rst one exothermic at 256 C which is due to
crystallization and the second one endothermic at 279 C which
is due to the VB2 melting. In the case of encapsulated VB2, the
peaks correspond to VB2 transitions have been disappeared and
the peaks in the curve are consistent with transitions of
CAbCDP. It is indicated that the preparation of VB2 loaded in
the polymer and also the amorphous dispersion of VB2 in the
CAbCDP.VB2 and CAbCDP-15/VB2
C-15 C-9 C-6 C-12
159.86 ppm 130.67 ppm 117.46 ppm 18.79 ppm
160.21 ppm 130.82 ppm 117.77 ppm 18.97 ppm
160.19 ppm 130.81 ppm 117.78 ppm 18.93 ppm
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Fig. 10 Zeta potential of VB2, CAbCDP-5/VB2 and CAbCDP-15/VB2 in
aqueous solution at 25 C.
Paper RSC AdvancesDLS analysis. This is one of the most popular technique
which is used to determine the size distribution prole of small
particles in suspension or polymers in solution. Fig. 9 shows the
results that have beenmeasured by DLS for an aqueous solution
of the VB2 and also CAbCDP-5 and CAbCDP-15 containing VB2.
These solutions were optically clear at ambient temperature;
but, the DLS intensity distribution indicated the existence of
small particles with a hydrodynamic radius of approximately
1281 nm, 255 nm and 338 nm for VB2, CAbCDP-5/VB2 and
CAbCDP-15/VB2, respectively. The size of loaded-VB2 in the
polymers were dramatically lower than VB2 alone. Based on the
evident of size determination studies, the size of loaded-VB2 in
the polymer was increased with increasing the GN ratio in the
cationic polymers from 5 to 15. These results suggest that the
VB2 can be formed as an eﬃciency complex with the CAbCDP
without any aggregate.
Zeta potential. Zeta potential is an essential instrument to
investigate the surface charges and host–guest interaction
types. Fig. 10 shows the zeta potential values that obtained for
the pure VB2 and loaded-VB2 in the CAbCDP-5 and CAbCDP-
15. These measurements were conducted in DI water to
avoid the inuence of pH transitions. The zeta potential of VB2
alone is around 30.6 mV, which could be increased to +10.9
and +11.3 mV aer being complexed with CAbCDP-5 and 15,
respectively. It was noted that the native VB2 has a negative
zeta potential, while the loaded-VB2 in CAbCDPs has a positive
zeta potential value which is indicated that the complexes
surface were positively charged due to the availability of the
C]NH2
+ groups in the b-CD polymer. These results suggested
that the VB2 are included in the cavities and networks of
CAbCDP, as well as the electrostatic attraction between the
anionic groups of VB2 and cationic groups of CAbCDP. As it is
expected, the zeta potential values of complexes increased with
increasing the GN amount due to the increased amount of
cationic groups in the CAbCDP.
Water solubility study. The water solubility data for VB2 and
VB2 in the presence of native b-CDs, NEbCDP, CAbCDP-5, 10
and 15 are summarized in Table 4. The VB2 is a poorly soluble
vitamin and its solubility in water obtained 0.078 mg mL1
which is in agreement with the literature.83,84 From Table 4, it
can be understand that CAbCDP/VB2 solubility is much higherFig. 9 Size distributions of VB2, CAbCDP-5/VB2 and CAbCDP-15/VB2
complexes in terms of volume in aqueous solution at 25 C.
This journal is © The Royal Society of Chemistry 2016than the VB2 and b-CD/VB2 solubility and slightly higher than
the NEbCDP/VB2 solubility. As a result, it can be concluded that
the VB2 solubility increases because of the formation of inclu-
sion complexes between VB2 and CAbCDPs. As it is concluded
from NMR data, benzene ring of VB2 molecule penetrates into
the b-CD cavity. This should be favorable for enhancement of
the aqueous solubility of vitamin. In addition, decreased crys-
tallinity coupled with zeta potential change are important
factors which is playing a positive role in increasing VB2 solu-
bility. It is clearly seen that the water solubility of all complexes
were obviously increased along with increasing of GN amount
(Table 4).Table 4 Solubility data of b-CD, NEbCDP, CAbCDP, VB2 and VB2 in the
presence of native b-CDs and b-CD polymers
Samples Solubility (g/1000 mL, 30 C)
VB2 0.078  1.1
b-CD 17.7  1.3
NEbCDP 875  3.6
CAbCDP-5 925  2.6
CAbCDP-10 1061  3.4
CAbCDP-15 1285  1.8
NEbCDP/VB2 394  3.1
CAbCDP-5/VB2 484  3.7
CAbCDP-10/VB2 536  4.1
CAbCDP-15/VB2 673  2.9
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Fig. 11 Cumulative release of VB2 from (A) CAbCDP-5 and (B) CAbCDP-15 for 1600 minute.
RSC Advances PaperIn vitro release studies
In this study, cumulative release of VB2 from CAbCDP-5 and 15
in gastric acidic (hydrochloric acid buﬀer, pH ¼ 1.2), in intes-
tinal (phosphate buﬀer, pH ¼ 7.4) and in alkaline conditions
(carbonate buﬀer, pH ¼ 10) were performed. For comparative
purposes in these experiments the cationic polymers with
diﬀerent amount of GN were chosen. The release of VB2 from
polymers were characterized over 26 h at 37 C, and the
percentage of vitamin release from these samples against the
time have been shown in Fig. 11A and B.
As it is expected, for two cationic polymers which possess
the cationic networks and hydrophobic cavity of b-CD, typi-
cally, a biphasic release prole can be observed in which
a burst release stage is followed by a sustained release phase
over the time (Fig. 11). The burst phase should be due to the
release of free VB2 molecule and the incorporated VB2 into the
networks through non-inclusion interactions. For the VB2
molecule that are associated with b-CD units through the
inclusion interactions, the release occurs through a slower
dissociation and diﬀusion. In the case of the CAbCDP-5
(Fig. 11A), more than 98.53% and 97.63% of the vitamin was
diﬀused out of the system at pH 10 and 1.2 aer 23 h respec-
tively. While approximately 81.5% of loaded-VB2 was released
from this polymer aer the same time at pH 7.4. On the other
hand, as it can be seen, the vitamin release rate from CAbCDP-
15 is slower than CAbCDP-5 with similar release proles in the
case of all the medium that have been studied (Fig. 11B).
Within 23 h nearly 89.1, 71.5% and 91.7% of loaded-VB2 was
released from CAbCDP-15 at pH 1.2, 7.4 and 10 into the
medium respectively. It can be observed that the amount of
released VB2 from the cationic polymers at pH 10 and 1.2 buﬀer
solution are higher than the pH 7.4 buﬀer solution, and also at
buﬀer solution with pH 10 the release is higher than buﬀer
solution with pH 1.2. Therefore, released VB2 from cationic
polymers is dependent on the medium pH and GN content
which the GN acts as a pH-response site to control vitamin
release. The decelerated release of VB2 under three conditions
from CAbCDP-15 in comparison with CAbCDP-5 may be due to33276 | RSC Adv., 2016, 6, 33267–33278the stronger electrostatic interactions between vitamin and
cationic polymer which is consistent with the result of NMR
analysis.Conclusions
In this work, we have prepared inclusion complexes between
VB2 and CAbCDPs using a co-precipitation method. The ob-
tained results from solid-state and solution show that the
vitamin capture and distribution in the cavities and
networks of cationic polymer. The size of loaded-VB2 in
cationic polymers are dramatically lower than native VB2
alone. The obtained complexes have a positive zeta potential,
while values of zeta potential for VB2 is negative, which is
indicated that the complexes surface is positively charged. In
addition, due to formation of complexes between VB2 and
highly water soluble cationic polymer, the vitamin solubility
is improved dramatically. It is clear that increasing GN
content in cationic polymers increases the water solubility of
all complexes. Proposed water-soluble CAbCDP is synthe-
sized by a simple and friendly environmental method. The
typical analyses revealed insertion of cationic GN in the
achieved polymeric structure. In here, the cumulative release
of VB2 from CAbCDPs in gastric acidic, intestinal and alka-
line conditions were performed. The results have been
illustrated a burst release stage and followed by a sustained
release stage over the time. Therefore, we think this new
prepared encapsulated VB2 can be considered with various
potential applications including in both food industry and in
pharmaceutical eld.Acknowledgements
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